© Reuters.
In a recent 8K filing with the SEC, Viracta Therapeutics (NASDAQ: VIRX) announced the resignation of Dan Chevallard, the company’s Chief Financial Officer and Chief Operating Officer, effective today. Mr. Chevallard has decided to step down from his roles to seek other opportunities.
The company clarified that Chevallard’s departure is voluntary and not due to any internal disputes regarding Viracta’s operations, policies, or practices. Viracta acknowledged Chevallard’s contributions over his tenure of nearly five years and expressed gratitude for his service.
Concurrent with his resignation, Viracta has entered into a consulting agreement with Chevallard, where he will continue to offer transition services to the company for a certain period.
In the interim, Melody Burcar, currently the Senior Vice President of Finance at Viracta, will assume the responsibilities of principal financial officer and principal accounting officer. The company has commenced the process of searching for a permanent successor to Chevallard.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.